Combination medicine for advanced liver cancer after prior treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two medicines (adebrelimab and apatinib) for people with advanced liver cancer who have already tried other treatments. The goal is to see if this combo can slow down the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have a confirmed diagnosis of liver cancer (hepatocellular carcinoma).
- Have already tried at least one type of cancer-fighting medicine (like targeted therapy, with or without immunotherapy).
- Be at a stage where surgery or local treatments are not possible or have already been done and the cancer has progressed.
- Have good liver function (Child-Pugh class A) and be able to do daily activities (ECOG 0-1).
- Have not previously received PD-L1 immunotherapy or apatinib.
- Not have an active autoimmune disease or other active cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This study tests a personalized combination treatment for unresectable (cannot be removed with surgery) liver cancer. It uses a special test to guide which drugs you receive, aiming to improve how well the treatment works for your specific tumor type.
This trial tests a combination of three drugs given before and after surgery for liver cancer that can be removed. The goal is to see if this approach can help reduce the chance of the cancer coming back.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.